Document:

EX-10.23

 Exhibit 10.23 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*****], HAS BEEN OMITTED BECAUSE ZIOPHARM ONCOLOGY, INC. HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZIOPHARM ONCOLOGY, INC. IF PUBLICLY DISCLOSED. 

PUBLIC HEALTH SERVICE 

Amendment 
 This Agreement
is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for
Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

National Cancer Institute 
 an
Institute or Center (hereinafter referred to as the “IC”) of the 
 NIH 

and 
 Ziopharm Oncology, Inc.,

 hereinafter referred to as the “Licensee”, 

having offices at One First Avenue, Parris Building #34, Navy Yard Plaza, Boston, MA 02129, 

created and operating under the laws of Delaware. 

Tax ID No.:
84-1475642                     

  
 A-506-2019 

 

					
	CONFIDENTIAL -NIH	  		  	

					
	First Amendment of L-190-2019/0	  	 Final     Ziopharm Oncology, Inc.
	  	December 16, 2019

					
	Model 10-2015	 	Page 1 of 6	 	

 FIRST AMENDMENT TO
L-190-2019/0 
 This is the first amendment (“First
Amendment”) of the agreement by and between the IC and Licensee having an effective date of May 28, 2019 and having IC Reference Number
L-190-2019/0 (“Agreement”). This First Amendment, having IC Reference Number L-190-2019/1 includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Royalty Payment Information), and 3) Appendix A- Patent(s) or
Patent Application(s). 
 WHEREAS, the IC and the Licensee desire that the Agreement be amended a first time as set forth below in
order to bring additional patent rights within the scope of the Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises
contained herein, the IC and the Licensee, intending to be bound, hereby mutually agree to the following: 
  

	1)	 The cover page’s “Serial Number(s) of Licensed Patent(s) or Patent Application(s)” section of
the Agreement shall be amended to include the following patent applications: 

  

	 	1.	 [***] 

  

	2)	 Appendix A - Patent(s) or Patent Application(s) of the Agreement shall be deleted and replaced with
Appendix A- Patent(s) or Patent Application(s) of this First Amendment. 

  

	3)	 Within sixty (60) days of the execution of this First Amendment, the Licensee shall
pay the IC an amendment issue royalty in the sum of six hundred thousand US Dollars ($600,000.00). Payment options may be found in Attachment 1. The parties agree that the foregoing payment obligation shall be in lieu of the non-creditable, non-refundable amendment issue royalty set forth in Paragraph VII of Appendix C of the Agreement for all Additional T Cell Receptors added pursuant to
this First Amendment. 

  

	4)	 In the event any provision(s) of the Agreement is/are inconsistent with Attachment 1, such provision(s)
is/are hereby amended to the extent required to avoid such inconsistency and to give effect to the payment information in such Attachment 1. 

  

	5)	 All terms and conditions of the Agreement not herein amended remain binding and in effect.

  

	6)	 The terms and conditions of this First Amendment shall, at the IC’s sole option, be
considered by the IC to be withdrawn from the Licensee’s consideration and the terms and conditions of this First Amendment, and the First Amendment itself, to be null and void,
unless this First Amendment is executed by the Licensee and a fully executed original is received by the IC within sixty (60) days from the date of the IC’s signature found at the Signature
Page. 

  

	7)	 This First Amendment is effective upon execution by all parties. 

SIGNATURES BEGIN ON NEXT PAGE 

  
 A-506-2019 

 

					
	CONFIDENTIAL -NIH	  		  	

					
	First Amendment of L-190-2019/0	  	 Final     Ziopharm Oncology, Inc.
	  	December 16, 2019

					
	Model 10-2015	 	Page 2 of 6	 	

 FIRST AMENDMENT TO
L-190-2019/0 
 SIGNATURE PAGE 

In Witness Whereof, the parties have executed this First Amendment on the dates set forth below. Any communication or notice to be given shall
be forwarded to the respective addresses listed below. 
 For the IC: 
  

					
	  
 Richard U. Rodriguez, MBA
	 		 	  
 Date

	Associate Director	 		 	
	Technology Transfer Center, National Cancer Institute	 		 	

 National Institutes of Health Mailing Address or E-mail Address for Agreement
notices and reports: 
 License Compliance and Administration 

Monitoring & Enforcement 
 Office of Technology Transfer

 National Institutes of Health 
 6011 Executive Boulevard,
Suite 325 
 Rockville, Maryland 20852-3804 U.S.A. 
 E-mail: LicenseNotices_Reports@mail.nih.gov 
 For the Licensee (Upon information and belief, the undersigned
expressly certifies or affirms that the contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

					
	  
 Signature of Authorized
Official
	 		 	  
 Date

			
	Name:	 		 	
	Title:	 		 	

  

	 	I.	 Official and Mailing Address for Agreement notices: 

 

					
		 	 Rob Hadfield
	 	
		 	Name	 	
			
		 	 General Counsel
	 	
		 	Title	 	
			
		 	Mailing Address:	 	

  
 A-506-2019 

 

					
	CONFIDENTIAL -NIH	  		  	

					
	First Amendment of L-190-2019/0	  	 Final     Ziopharm Oncology, Inc.
	  	December 16, 2019

					
	Model 10-2015	 	Page 3 of 6	 	

					
		 	 One First Avenue, Parris Building #34
	 	
		 	 Navy Yard Plaza
	 	
		 	 Boston, MA 02129
	 	
		 	  
	 	

  

							
		 	Email Address:	  	 [***]
	  	
				
		 	Phone:	  	 [***]
	  	
				
		 	Fax:	  	 [***]
	  	

  

	 	II.	 Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty
payments): 

  

					
		  	 Eshane Dupre
	 	
		  	Name	 	
			
		  	 Accounts Payable
	 	
		  	Title	 	
			
		  	Mailing Address:	 	
			
		  	 One First Avenue, Parris Building #34
	 	
		  	 Navy Yard Plaza
	 	
		  	 Boston, MA 02129
	 	
		  	  
	 	

  

							
		 	Email Address:	  	 [***]
	  	
				
		 	Phone:	  	 [***]
	  	
				
		 	Fax:	  	 [***]
	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C.
§§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment). 

  
 A-506-2019 

 

					
	CONFIDENTIAL -NIH	  		  	
	First Amendment of L-190-2019/0	  	 Final     Ziopharm Oncology, Inc.
	  	December 16, 2019

					
	Model 10-2015	 	Page 4 of 6	 	

 ATTACHMENT 1 – ROYALTY PAYMENT INFORMATION 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

[***] 

  
 A-506-2019 

 

					
	CONFIDENTIAL -NIH	  		  	

					
	First Amendment of L-190-2019/0	  	 Final     Ziopharm Oncology, Inc.
	  	December 16, 2019

					
	Model 10-2015	 	Page 5 of 6	 	

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 
 Group A 

[***] 
 Group B 

[***] 
 Group C 

[***] 
 Group D 

[***] 
 Group E 

[***] 
 Group F 

[***] 

  
 A-506-2019 

 

					
	CONFIDENTIAL -NIH	  		  	

					
	First Amendment of L-190-2019/0	  	 Final     Ziopharm Oncology, Inc.
	  	December 16, 2019

					
	Model 10-2015	 	Page 6 of 6Exhibit

Exhibit 4.62

DESCRIPTION OF THE REGISTRANTS’ SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

EVERGY, INC.

As of February 14, 2020, Evergy, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. 

Description of Common Stock of Evergy, Inc.
The following descriptions of our common stock and the relevant provisions of our Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and Amended and Restated By-laws (the “By-laws”) are summaries and are qualified by references to the Articles of Incorporation and the By-laws, each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K of which this Exhibit is a part, as well as the applicable General and Business Corporation Law of Missouri.
General
Under the Articles of Incorporation, we are authorized to issue 612,000,000 shares of stock, divided into classes as follows:
 
		
	•
	12,000,000 shares of preference stock without par value (“Preference Stock”); and

		
	•
	600,000,000 shares of common stock without par value (“Common Stock”).

 
No shares of our Preference Stock are currently outstanding.
Dividend Rights and Limitations
The holders of our Common Stock are entitled to receive such dividends as our Board of Directors may from time to time declare, subject to any rights of the holders of our Preference Stock. Our ability to pay dividends depends primarily upon the ability of our subsidiaries to pay dividends or otherwise transfer funds to us.
Voting Rights
Except as otherwise provided by law and subject to the voting rights of any outstanding Preference Stock, the holders of our Common Stock are entitled to one vote for each share on all matters voted on by shareholders, including the election of directors. The holders of our Common Stock are not entitled to cumulative voting of their shares in the election of directors. Directors are to be elected by a majority of the votes cast by the holders of Common Stock entitled to vote and present in person or represented by proxy, provided that in the case of a “contested election” (as such term is defined in the By-laws), the directors will be elected by a plurality of the votes cast. 

Liquidation Rights
In the event of any dissolution or liquidation of Evergy, Inc., after there shall have been paid to or set aside for the holders of shares of any outstanding Preference Stock the full preferential amounts to which they are entitled, the holders of outstanding shares of Common Stock shall be entitled to receive pro rata, according to the number of shares held by each, the remaining assets available for distribution.
Miscellaneous
The outstanding shares of our Common Stock are fully paid and non-assessable.  The holders of our Common Stock are not entitled to any preemptive or preferential rights to subscribe for or purchase any part of any new or additional issue of stock or securities convertible into stock. Our Common Stock does not contain any sinking fund provisions, redemption provisions or conversion rights.
Transfer Agent and Registrar
Computershare Trust Company, N.A. acts as transfer agent and registrar for our Common Stock.

Business Combinations
The affirmative vote of the holders of at least 80% of the outstanding shares of Common Stock is required for the approval or authorization of certain business combinations with interested shareholders; provided, however, that such 80% voting requirement shall not be applicable if:

		
	•
	the business combination shall have been approved by a majority of the continuing directors; or

		
	•
	the cash or the fair market value of the property, securities, or other consideration to be received per share by holders of the Common Stock in such business combination is not less than the highest per share price paid by or on behalf of the interested shareholder for any shares of Common Stock during the five-year period preceding the announcement of the business combination.

 
 Listing
The Common Stock of Evergy, Inc. is listed on the New York Stock Exchange LLC under the symbol “EVRG.”

EVERGY KANSAS CENTRAL, INC.

As of February 14, 2020, Evergy Kansas Central, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.  As of that date, one share of Evergy Kansas Central, Inc.’s common stock is outstanding and held by Evergy, Inc., the parent company of Evergy Kansas Central, Inc. 

Description of Common Stock of Evergy Kansas Central, Inc.
The following descriptions of our common stock and the relevant provisions of our Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and Amended and Restated By-laws (the “By-laws”) are summaries and are qualified by references to the Articles of Incorporation and the By-laws, each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K of which this Exhibit is a part, as well as the applicable Kansas General Corporation Code.
General
Under the Articles of Incorporation, we are authorized to issue 1,000 shares of common stock, par value $0.01 per share (“Common Stock”). 
Voting Rights
Except as otherwise provided by law, the holders of our Common Stock are entitled to one vote for each share on each matter submitted at a meeting of the shareholders and for the election of directors through cumulative voting. Cumulative voting means each shareholder has a total vote equal to the number of shares they own multiplied by the number of directors to be elected. These votes may be divided among all nominees equally or may be voted for one or more of the nominees either in equal or unequal amounts. The nominees with the highest number of votes are elected. including the election of directors. 
Miscellaneous
The outstanding share of our Common Stock is fully paid and non-assessable.  Our Common Stock does not contain any sinking fund provisions, redemption provisions or conversion rights.
No Listing
The Common Stock of Evergy Kansas Central, Inc. is not listed on any securities exchange.

EVERGY METRO, INC.

As of February 14, 2020, Evergy Metro, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock.  As of that date, one share of Evergy Metro, Inc.’s common stock is outstanding and held by Evergy, Inc., the parent company of Evergy Metro, Inc.

Description of Common Stock of Evergy Metro, Inc.
The following descriptions of our common stock and the relevant provisions of our Amended and Restated Articles of Consolidation (the “Articles of Consolidation”) and Amended and Restated By-laws (the “By-laws”) are summaries and are qualified by references to the Articles of Consolidation and the By-laws, each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K of which this Exhibit is a part, as well as the applicable General and Business Corporation Law of Missouri.
General
Under the Articles of Consolidation, we are authorized to issue 1,000 shares of common stock without par value (“Common Stock”). 
Dividend Rights 
The holders of our Common Stock are entitled to receive such dividends out of any funds legally available for the purpose, when and as declared by our Board of Directors.
Voting Rights
Except as otherwise provided by law, the holders of our Common Stock are entitled to one vote for each share on each matter submitted at a meeting of the shareholders and for the election of directors through cumulative voting. Cumulative voting means each shareholder has a total vote equal to the number of shares they own multiplied by the number of directors to be elected. These votes may be divided among all nominees equally or may be voted for one or more of the nominees either in equal or unequal amounts. The nominees with the highest number of votes are elected. including the election of directors. 
Liquidation Rights
In the event of any dissolution or liquidation of Evergy Metro, Inc., after there shall have been paid to or set aside for the holders of any outstanding shares having superior liquidation preferences to Common Stock the full preferential amounts to which they are entitled, the holders of outstanding shares of Common Stock shall be entitled to receive pro rata, according to the number of shares held by each, the remaining assets available for distribution.
Miscellaneous
The outstanding share of our Common Stock is fully paid and non-assessable.  The holders of our Common Stock are not entitled to any preemptive right to subscribe for or acquire any shares of stock or any securities of any kind issued by Evergy Metro, Inc.  Our Common Stock does not contain any sinking fund provisions, redemption provisions or conversion rights.

Business Combinations
The affirmative vote of the holders of at least 80% of the outstanding shares of Common Stock is required for the approval or authorization of certain business combinations with interested shareholders; provided, however, that such 80% voting requirement shall not be applicable if:
		
	•
	the business combination shall have been approved by a majority of the continuing directors; or

		
	•
	the cash or the fair market value of the property, securities, or other consideration to be received per share by holders of the Common Stock in such business combination is not less than the highest per share price paid by or on behalf of the interested shareholder for any shares of Common Stock during the five-year period preceding the announcement of the business combination.

No Listing
The Common Stock of Evergy Metro, Inc. is not listed on any securities exchange.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]